STEVEN I SHERMAN to Pyrimidines
This is a "connection" page, showing publications STEVEN I SHERMAN has written about Pyrimidines.
Connection Strength
0.179
-
ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of RET, VEGFR2, and IGFBP2. Mol Cancer Ther. 2021 04; 20(4):665-675.
Score: 0.076
-
Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab. 2009 Dec; 23(6):713-22.
Score: 0.035
-
Early clinical studies of novel therapies for thyroid cancers. Endocrinol Metab Clin North Am. 2008 Jun; 37(2):511-24, xi.
Score: 0.032
-
Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies. ESMO Open. 2020 10; 5(5):e000799.
Score: 0.019
-
A Phase I Trial of the VEGF Receptor Tyrosine Kinase Inhibitor Pazopanib in Combination with the MEK Inhibitor Trametinib in Advanced Solid Tumors and Differentiated Thyroid Cancers. Clin Cancer Res. 2019 09 15; 25(18):5475-5484.
Score: 0.017